Demchuk, MariyaIvankova, OlenaKlunnyk, MariyaMatiyashchuk, IrynaSych, NataliiaSinelnyk, AndriyNovytska, Dr. AllaSorochynska, Khrystyna2017-05-272017-05-272016Efficacy of Fetal Stem Cells Use in Complex Treatment of Patients With Insulin-resistant Type 2 Diabetes Mellitus [electronic resource] / M. Demchuk, O. Ivankova, M. Klunnyk, I. Matiyashchuk, N. Sych, A. Sinelnyk, A. Novytska, K. Sorochynska // Journal of Stem Cell Research & Therapy. - 2016. - Vol. 6, Issue 6. - 7 p. - Метод доступу: Інтернет. - doi:10.4172/2157-7633.1000342 (переглянуто 26 травня 2017 р.). - Назва з екрана.https://ekmair.ukma.edu.ua/handle/123456789/11419Objective: To identify efficacy of fetal stem cells in treatment of the patients suffering from Type 2 diabetes mellitus in presence of insulin resistance and to summarize all characteristics of post-transplantation disease course. Materials and methods: 42 patients suffering from Type 2 diabetes mellitus (T2DM) in presence of insulin resistance were examined including 27 men and 15 women. Glycaemia ranges were controlled by diet therapy in 7 patients (16.7%), whereas the rest of the patients were recommended antihyperglycemic medicines (biguanides, thiazolidinediones, sulfonylurea derivatives and a-reductase inhibitors). Fetal stem cells (FSCs) were administered in complex therapy for the patients with T2DM and the data of clinical, laboratory and anthropometric investigations were analyzed over the study period. Results: Positive effects to values of carbohydrate and lipid metabolism, as well as arterial blood pressure (ABP) in T2DM have been justified. FSCs capacity to decreasing insulin resistance (in accordance with the HOMA-IR scale) which results in stable continuous diabetes mellitus compensation was established. Conclusion: FSCs use in complex treatment of patients with T2DM stabilizes disease compensation and leads to decrease in hyperinsulinemia and lower insulin resistance.enFetal stem cellsInsulin resistanceTreatment of type 2 diabetes mellitusArticle